Law, ethics and medicine
A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
Other content recommended for you
- Should rare diseases get special treatment?
- Rare neurological diseases: a practical approach to management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Ethical issues in funding orphan drug research and development
- Orphan drugs and the NHS: should we value rarity?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
- Commissioning for rare diseases: view from the frontline